Olmesartán Sandoz (Olmesartan Medoxomil)

Olmesartan Medoxomil, the active ingredient in Olmesartán Sandoz, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It lowers elevated blood pressure by selectively blocking the AT1 receptor, helping to reduce the risk of cardiovascular complications in adults with hypertension.

GNH USA supplies Olmesartán Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets through established distribution networks.

Olmesartan Medoxomil is an ARB indicated for the management of hypertension and related cardiovascular conditions. - Essential hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. - Hypertension with cardiovascular risk: contributes to blood pressure control, reducing strain on the heart and vessels. - Hypertension in elderly patients: provides effective blood pressure reduction with a favorable tolerability profile.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: occasional dry throat irritation. - Hyperkalemia (mild): slight increase in blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Severe hyperkalemia: marked elevation of potassium that can affect heart rhythm. - Acute renal impairment: sudden decline in kidney function. - Hypotension: significant drop in blood pressure causing faintness. - Hepatic injury: abnormal liver enzyme elevations. - Neutropenia: reduced neutrophil count increasing infection risk.

Patients should be monitored for safety and appropriate use. - Monitor blood pressure: ensure therapeutic targets are achieved without excessive lowering. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium levels to avoid hyperkalemia. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid in pregnancy: potential fetal harm; discontinue if pregnancy is confirmed. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Olmesartan may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase risk of renal dysfunction. - Potassium‑sparing diuretics: may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use raises hyperkalemia and renal impairment risk. - Lithium: increased lithium levels leading to toxicity. - NSAIDs (high dose): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect. - CYP3A4 inhibitors (e.g., ketoconazole): can raise olmesartan plasma concentrations. - NSAIDs (regular use): monitor renal function and blood pressure. - Antidiabetic agents: blood glucose may improve, requiring dose adjustment. - Rifampin: may reduce olmesartan effectiveness by increasing metabolism.